FUNDING CANCER - Assay Validation of High-Quality Markers for Clinical Studies in Cancer (Multiple Mechanisms)
Sponsor: NIH
Multiple Mechanisms:
PAR-25-074, UH2/UH3 Clinical Trial Not Allowed
PAR-25-075, UH3 Clinical Trials Not Allowed
Description: Through this NOFO, the National Cancer Institute invites applications to support the validation of biomarkers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response to treatment, as well as markers for cancer prevention and control. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. The UH2 phase of this NOFO supports analytical validation of assays, which must be achieved within two years before assays may undergo clinical validation. The UH3 phase supports clinical validation of analytically validated assays for up to three years using well-annotated biospecimens from retrospective or prospective studies.
- Applications Due:
- February 14, 2025
- June 11, 2025
- October 15, 2025
- February 13, 2026
- June 10, 2026
- October 14, 2026
To view all current UVACCC funding opportunities, please click here.
For all open cancer-related funding opportunities, please click here.